RESEARCH TRIANGLE PARK, N.C. / May 16, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has announced a strategic collaboration with the contract research organization arm of Sarah Cannon Research Institute, SCRI Development Innovations, aimed at transforming oncology trials for... Read More

RESEARCH TRIANGLE PARK, N.C. / May 07, 2025 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Bank of America Annual Health Care Conference on Tuesday, May 13, 2025, at 5:20 p.m. ET (2:20 p.m. local PT). A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at... Read More

Revenue of $3,829 million GAAP Net Income of $249 million, Adjusted EBITDA of $883 million GAAP Diluted Earnings per Share of $1.40, Adjusted Diluted Earnings per Share of $2.70 R&D Solutions quarterly bookings of $2.1 billion, resulting in trailing-twelve-month bookings of $9.7 billion and a trailing-twelve-month book-to-bill ratio of 1.14x R&D Solutions contracted backlog of $31.5 billion, up 4.8 percent year-over-year TAS... Read More

RESEARCH TRIANGLE PARK, N.C. / Apr 28, 2025 / Business Wire / IQVIA™ (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Marie E. Lamont, head of Real World Solutions (Patient Insights, Experience and Registry Solutions), and Dr. Joanne Hackett, vice president, Health System Services (Europe,... Read More

RESEARCH TRIANGLE PARK, N.C. / Apr 23, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced today that the global independent research and analysis firm Everest Group ® has named IQVIA a “front-runner generative AI leader” for the life sciences industry in its recent report, “ AI-deas to Action: Operationalizing Generative... Read More

RESEARCH TRIANGLE PARK, N.C. / Apr 21, 2025 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations... Read More

Research and development funding has increased: Biopharma funding increased for the second consecutive year in 2024. Total large-pharma R&D spending continued to increase. Clinical trial start volumes have stabilized: Trial starts have fully returned to pre-pandemic levels. Priorities have continued to shift. Clinical program productivity has increased: Improvement in productivity was driven by a success-rate increase in... Read More

RESEARCH TRIANGLE PARK, N.C. / Mar 10, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life sciences industries, has been named to the “Leaders” category of the IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions and Consulting Services 2024 Vendor Assessment. IDC, a... Read More

RESEARCH TRIANGLE PARK, N.C. / Mar 04, 2025 / Business Wire / IQVIA Laboratories , a leading global drug discovery and development laboratory services organization, announces the launch of Site Lab Navigator, an advanced suite of solutions that automates and streamlines lab workflows for clinical trial sponsors and investigator sites. At the core of Site Lab Navigator is a new, innovative e-Requisition solution, which allows... Read More

RESEARCH TRIANGLE PARK, N.C. / Feb 24, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences and healthcare industries, today announced that IQVIA AI Assistant has been awarded a 2024 PM360 Innovation Award in the Artificial Intelligence category. Launched in September 2024, IQVIA AI Assistant revolutionizes insight... Read More

RESEARCH TRIANGLE PARK, N.C. / Feb 21, 2025 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the TD Cowen Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com . A replay... Read More

RESEARCH TRIANGLE PARK, N.C. / Feb 20, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has published its 2024 Sustainability Report. The report details IQVIA’s sustainability achievements consistent with its mission to accelerate innovation for a healthier world. “IQVIA combines... Read More

Revenue of $3,958 million for the fourth quarter, $15,405 million for the full year GAAP Net Income of $437 million for the fourth quarter, $1,373 million for the full year Adjusted EBITDA of $996 million for the fourth quarter, $3,684 million for the full year GAAP Diluted Earnings per Share of $2.42 for the fourth quarter, $7.49 for the full year Adjusted Diluted Earnings per Share of $3.12 for the fourth quarter, $11.13... Read More

RESEARCH TRIANGLE PARK, N.C. / Feb 04, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2025 Fortune ® World’s Most Admired Companies ™ list. This is the fourth year in a row IQVIA has earned first place in the Health Care: Pharmacy and Other Services category, and the eighth consecutive... Read More

RESEARCH TRIANGLE PARK, N.C. / Jan 21, 2025 / Business Wire / IQVIA Holdings Inc . (“IQVIA”) (NYSE:IQV) will announce its fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the... Read More

RESEARCH TRIANGLE PARK, N.C. / Jan 13, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights, and healthcare intelligence, today announced a strategic collaboration with NVIDIA to help realize the potential of AI in healthcare and life sciences. The healthcare and life sciences industries generate vast amounts of data, representing significant potential for... Read More

The number of digital health apps stands at 337,000, with disease-specific apps that bring more value to health systems growing in number and their focus expanding beyond mental health and chronic diseases to encompass other conditions. Approval and reimbursement of digital tools is accelerating as payers recognize clinical utility and cost savings; of the more than 360 software-based digital therapies commercially... Read More

RESEARCH TRIANGLE PARK, N.C. / Nov 06, 2024 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the UBS Healthcare Conference in Rancho Palos Verdes, California on Wednesday, November 13, 2024 at 1:15 p.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at... Read More

Revenue of $3,896 million GAAP Net Income of $285 million, Adjusted EBITDA of $939 million GAAP Diluted Earnings per Share of $1.55, Adjusted Diluted Earnings per Share of $2.84 R&D Solutions quarterly bookings of $2.3 billion, resulting in trailing-twelve-month bookings of $10.4 billion and a trailing-twelve-month book-to-bill ratio of 1.22x R&D Solutions contracted backlog of $31.1 billion, up 8.0 percent reported... Read More

RESEARCH TRIANGLE PARK, N.C. / Oct 15, 2024 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2024 financial results before the market opens on Thursday, October 31, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor... Read More

RESEARCH TRIANGLE PARK, N.C. / Oct 02, 2024 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today introduces IQVIA AI Assistant, a generative AI technology that enables a step-change enhancement in how life science customers receive timely and powerful insights. IQVIA AI Assistant is a... Read More

Award Recognizes Leadership in AI Regulatory and Quality Solutions for Healthcare RESEARCH TRIANGLE PARK, N.C. / Sep 19, 2024 / Business Wire / IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Frost & Sullivan, a leading independent research and consulting firm, has awarded IQVIA with the 2024 Global... Read More

RESEARCH TRIANGLE PARK, N.C. / Aug 21, 2024 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Morgan Stanley Annual Healthcare Conference in New York on Wednesday, September 4, 2024 at 10:00 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at... Read More

Revenue of $3,814 million GAAP Net Income of $363 million, Adjusted EBITDA of $887 million GAAP Diluted Earnings per Share of $1.97, Adjusted Diluted Earnings per Share of $2.64 R&D Solutions quarterly bookings of $2.7 billion, representing a book-to-bill ratio of 1.27x R&D Solutions contracted backlog of $30.6 billion, up 7.7 percent reported and 8.1 percent at constant currency year-over-year Full-year 2024 guidance... Read More

RESEARCH TRIANGLE PARK, N.C. / Jul 11, 2024 / Business Wire / IQVIA ™ (NYSE:IQV) today announces that a leading, independent research firm, Everest Group, has recognized IQVIA as a Leader in its Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment 2024 survey, which measures both market impact and delivery effectiveness. The Everest Group report highlights IQVIA’s focus on innovation and its... Read More

RESEARCH TRIANGLE PARK, N.C. / Jul 08, 2024 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its second-quarter 2024 financial results before the market opens on Monday, July 22, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor... Read More

RESEARCH TRIANGLE PARK, N.C. / Jun 25, 2024 / Business Wire / IQVIA™ (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the IQVIA SmartSolve Enterprise Quality Management System (eQMS) platform has been selected as the winner of the “Best Use of Artificial Intelligence in Healthcare" award in the 8 th Annual... Read More

Bold initiative to boost the capacity of research sites enters Beta testing and piloting RESEARCH TRIANGLE PARK, N.C. / Jun 12, 2024 / Business Wire / IQVIA (NYSE:IQV) today announced the launch of One Home for Sites™, a new technology platform that acts as a single sign-on and a single dashboard for the key systems and tasks a clinical research site needs to perform across all of the clinical trials it is conducting.... Read More

Cancer incidence is expected to rise significantly through 2050, particularly in lower-income countries, to 32 million new cases annually – a potential increase of more than 12 million new annual cases Global spending on cancer medicine increased to $223 billion in 2023, $25 billion more than in 2022, and is projected to reach $409 billion by 2028 In 2023, 25 oncology novel active substances (NASs) were launched globally,... Read More

Overall spending in the U.S. market for medicines grew 2.5% in 2023, reaching $435Bn at net price level, reflecting a sharp decline in COVID-19 vaccines and therapeutics Spending growth was 9.9% when COVID-19 vaccines and therapeutics are excluded, driven by innovation in areas such as oncology, immunology, diabetes, and obesity Patient out-of-pocket costs increased due to the increasing use of GIP/GLP-1 agonists, which are... Read More

RESEARCH TRIANGLE PARK, N.C. / May 09, 2024 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Bank of America Health Care Conference in Las Vegas on Tuesday, May 14, 2024 at 12:20 p.m. ET (9:20 a.m. local PT). A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at... Read More

Revenue of $3,737 million GAAP Net Income of $288 million, Adjusted EBITDA of $862 million GAAP Diluted Earnings per Share of $1.56, Adjusted Diluted Earnings per Share of $2.54 R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.23x R&D Solutions contracted backlog of $30.1 billion, up 7.9 percent year-over-year RESEARCH TRIANGLE PARK, N.C. / May 02, 2024 / Business Wire / IQVIA Holdings... Read More

RESEARCH TRIANGLE PARK, N.C. / Apr 23, 2024 / Business Wire / IQVIA (NYSE:IQV) today announced that Wendy Stewart, president of Clinical Operations at IQVIA, and Susan Barnes, senior director of IQVIA Biotech Strategic Operations, have been honored with the Healthcare Businesswoman's Association Luminary and Rising Star Awards, respectively. Wendy earned the award for her remarkable contributions to the healthcare industry,... Read More

RESEARCH TRIANGLE PARK, N.C. / Apr 15, 2024 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2024 financial results before the market opens on Thursday, May 2, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor... Read More

RESEARCH TRIANGLE PARK, N.C. & SAN FRANCISCO, CA / Apr 08, 2024 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Salesforce (NYSE:CRM), the #1 AI CRM, today announced an expanded global strategic partnership to accelerate the development of Salesforce’s Life Sciences Cloud, a next-generation customer engagement platform for the global... Read More

RESEARCH TRIANGLE PARK, N.C. / Mar 06, 2024 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024 at 9:30 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at... Read More

RESEARCH TRIANGLE PARK, N.C. / Feb 26, 2024 / Business Wire / IQVIA™ (NYSE:IQV), has published its 2023 Environmental, Social and Governance (ESG) Report. The annual report provides a detailed account of the organization’s focus on reducing its environmental impact and commitment to accelerating positive outcomes for public health and patients. “At IQVIA our mission is to accelerate innovation for a healthier world. Our... Read More

Clinical development productivity rose in 2023, primarily due to an improvement in the composite success rate, a function of phases successfully completed in the year, which rose to 10.8%. This was the highest level since 2018. Industry and regulator adoption of innovative and technology-driven enablers contributed to productivity gains. These enablers included the use of predictive biomarkers, novel trial design, and... Read More

RESEARCH TRIANGLE PARK, N.C. / Feb 21, 2024 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at Citi’s 2024 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 29, 2024 at 9:30 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at... Read More

Revenue of $3,868 million for the fourth quarter, $14,984 million for the full year GAAP Net Income of $469 million for the fourth quarter, $1,358 million for the full year Adjusted EBITDA of $966 million for the fourth quarter, $3,569 million for the full year GAAP Diluted Earnings per Share of $2.54 for the fourth quarter, $7.29 for the full year Adjusted Diluted Earnings per Share of $2.84 for the fourth quarter, $10.20... Read More

RESEARCH TRIANGLE PARK, N.C. / Feb 06, 2024 / Business Wire / IQVIA ™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to the Fortune® World's Most Admired Companies™ list for the seventh consecutive year. For the third year in a row IQVIA earned the first-place ranking within the Health Care: Pharmacy and Other... Read More

INNOVATION PARK, N.C. / Jan 24, 2024 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its fourth-quarter and full-year 2023 financial results before the market opens on Wednesday, February 14, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA... Read More

Growth outlook is raised by 2 percentage points despite lower expectations for COVID-19 vaccines and therapeutics This increase in growth outlook is driven by more patients getting treated with better medicines, especially in immunology, endocrinology, and oncology Medicine use in Latin America and Asia will grow faster than other regions over the next five years Global use of medicines grew by 14% over the past five years... Read More

INNOVATION PARK, N.C. / Nov 29, 2023 / Business Wire / IQVIA™ (NYSE:IQV), a leading global provider of data, analytics, technology solutions and services to the life sciences industry, today announced that IQVIA Digital Enablement has been named a PM360 Trailblazer 2023 Company of the Year in the Supplier/Vendor category. Nominations for the PM360 Trailblazer Awards, which recognize outstanding achievement and innovation in... Read More

INNOVATION PARK, N.C. / Nov 21, 2023 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Evercore Annual HealthCONx Conference in Miami on Wednesday, November 29, 2023 at 10:50 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com . A... Read More

INNOVATION PARK, N.C. / Nov 17, 2023 / Business Wire / IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Borrower”), allocated a new term B loan due 2031 of approximately $1,500 million (the “New Term Loan B”), which was upsized due to lender demand. The proceeds from the New Term Loan B, together with the proceeds from the Borrower’s offering of $1,250 million... Read More

INNOVATION PARK, N.C. / Nov 15, 2023 / Business Wire / IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer” or “Borrower”), priced an offering of $1,250 million in aggregate principal amount of senior secured notes due 2029 (the “Notes”), which was upsized due to strong demand. Substantially concurrently with the closing of this offering, the Borrower... Read More

INNOVATION PARK, N.C. / Nov 14, 2023 / Business Wire / IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer” or “Borrower”), intends to raise $500,000,000 through an offering of senior secured notes due 2029 (the “Notes”). Substantially concurrently with the closing of this offering, the Borrower intends to amend its senior secured credit facilities (the... Read More

RESEARCH TRIANGLE PARK, N.C. / Nov 06, 2023 / Business Wire / IQVIA™ (NYSE:IQV), a global provider of data, analytics, technology solutions and services to the life sciences industry, announced that Dr. Christina Mack, chief scientific officer, has been named to the 2023 PharmaVoice 100 list. The PharmaVoice 100, an industry-acclaimed honor now in it’s 18 th year, recognizes trailblazers and leaders who have built and... Read More

Revenue of $3,736 million grew 4.9 percent year-over-year GAAP Net Income of $303 million grew 7.1 percent year-over-year Adjusted EBITDA of $888 million grew 9.1 percent year-over-year GAAP Diluted Earnings per Share of $1.63 grew 9.4 percent year-over-year Adjusted Diluted Earnings per Share of $2.49 grew 0.4 percent year-over-year R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.24x... Read More

Sanofi to use IQVIA’s CRM platform to maximize customer interactions and innovate in the retail channel RESEARCH TRIANGLE PARK, N.C. / Oct 23, 2023 / Business Wire / IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announced that Sanofi will use the IQVIA OCE platform in select countries... Read More

CEPI will harness IQVIA’s expertise and resources in implementing global clinical research strategies and procedures to rapidly initiate clinical evidence generation around vaccines and other biological countermeasures in response to future health emergencies. Collaboration will also support a multi-regional research preparedness initiative to strengthen clinical research capacity in Low- and Middle-Income Countries, with an... Read More

RESEARCH TRIANGLE PARK, N.C. / Oct 09, 2023 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2023 financial results before the market opens on Wednesday, November 1, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor... Read More

There are more than 3,000 active patient organizations across the U.S., supporting patients through their health journeys and shaping research and care delivery Patient organizations are assuming an ever-expanding role, including developing patient registries to better understand diseases and funding scientific research to find cures The 21 st Century Cures Act required changes that are expanding the role of patient... Read More

RESEARCH TRIANGLE PARK, N.C. / Oct 03, 2023 / Business Wire / IQVIA ™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a strategic collaboration with argenx to advance treatment to patients with rare autoimmune diseases through innovative and integrated technology-enabled pharmacovigilance (PV) safety services and... Read More

RESEARCH TRIANGLE PARK, N.C. / Sep 25, 2023 / Business Wire / IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced... Read More

RESEARCH TRIANGLE PARK, N.C. / Sep 12, 2023 / Business Wire / IQVIA™ (NYSE:IQV), a global provider of data, analytics, technology solutions and services to the life sciences industry, has been named a Leader in the IDC Marketscape Worldwide Life Science R&D Pharmacovigilance Solutions 2022 Vendor Assessment. Fueled by IQVIA Connected Intelligence™, IQVIA offers a full suite of PV technologies and services to support... Read More

RESEARCH TRIANGLE PARK, N.C. / Sep 05, 2023 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Baird 2023 Global Healthcare Conference in New York City on Wednesday, September 13, 2023 at 10:50 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at... Read More

RESEARCH TRIANGLE PARK, N.C. / Sep 01, 2023 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Morgan Stanley Annual Global Healthcare Conference in New York City on Tuesday, September 12, 2023 at 11:30 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at... Read More

Revenue of $3,728 million grew 5.3 percent year-over-year on a reported basis and 5.5 percent at constant currency GAAP Net Income of $297 million grew 16.0 percent year-over-year Adjusted EBITDA of $864 million grew 8.0 percent year-over-year GAAP Diluted Earnings per Share of $1.59 grew 18.7 percent year-over-year Adjusted Diluted Earnings per Share of $2.43 declined 0.4 percent year-over-year R&D Solutions quarterly... Read More

RESEARCH TRIANGLE PARK, N.C. / Jul 06, 2023 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its second-quarter 2023 financial results before the market opens on Tuesday, August 1, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor... Read More

RESEARCH TRIANGLE PARK, N.C. / Jul 05, 2023 / Business Wire / IQVIA ™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, today announced that it has been recognized along with the National Basketball Association and partners at Harvard, Columbia and BioReference Laboratories for its work in supporting the league with the 2020 NBA... Read More

RESEARCH TRIANGLE PARK, N.C. / Jun 29, 2023 / Business Wire / IQVIA™ (NYSE:IQV), a global provider of data, analytics, technology solutions and services to the life sciences industry, was recognized as the highest scoring provider in the ‘Leader’ category of Everest Group’s Life Sciences Sales and Marketing Operations PEAK Assessment. This assessment included 17 providers and measured them according to two metrics: the... Read More

RESEARCH TRIANGLE PARK, N.C. / Jun 27, 2023 / Business Wire / IQVIA ™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, today announced that it has been selected as winner of the “Best AI-based Solution for Healthcare” award in the sixth annual AI Breakthrough Awards , a leading market intelligence organization that recognizes the... Read More

INNOVATION PARK, N.C. / Jun 26, 2023 / Business Wire / IQVIA™ (NYSE:IQV) today announced the launch of IQVIA RIM Smart Labeling , a comprehensive labeling solution for the life sciences industry that provides an intelligence-driven approach for more efficient and compliant global label management. Through this unique solution, life sciences companies can consolidate regulatory label planning, tracking and execution systems... Read More

RESEARCH TRIANGLE PARK, N.C. / May 25, 2023 / Business Wire / IQVIA ™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, announced a groundbreaking partnership today with (RED), the organization co-founded by Bono and Bobby Shriver to fight AIDS and the injustices that enable pandemics to thrive, to support laboratory system... Read More

Spending on cancer medicines is expected to reach $375Bn globally by 2027, up from $196Bn in 2022 For approved medicines, the number of patients treated globally has increased annually by an average of 5% over the past five years Oncology trial starts remained at historically high levels in 2022, up 22% from 2018 Emerging biopharma companies led innovation in oncology in 2022 and account for 71% of the pipeline Oncology... Read More

INNOVATION PARK, N.C. / May 18, 2023 / Business Wire / IQVIA Holdings Inc . (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $1,250,000,000 in aggregate principal amount of senior notes, which was upsized due to strong demand, consisting of $750,000,000 in aggregate principal amount of senior secured notes due 2028 (the “Senior Secured Notes”) and $500,000,000 in... Read More

INNOVATION PARK, N.C. / May 18, 2023 / Business Wire / IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $1,000,000,000 through an offering of senior secured notes due 2028 and senior notes due 2030 (collectively, the “Notes”). The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer’s revolving credit facility... Read More

RESEARCH TRIANGLE PARK, N.C. / May 11, 2023 / Business Wire / IQVIA (NYSE:IQV) today announced that Sheetal Telang, vice president of Therapeutic Strategy, has been honored with the 2023 Rising Star award by the Healthcare Businesswoman's Association (HBA). Sheetal earned the award for her strong and innovative leadership, combined with her exemplary work in IQVIA’s clinical development business. Sheetal has consistently... Read More

The U.S. market for medicines grew by 5% in 2022, reaching a total value of $429Bn Health services utilization reached 100% of pre-pandemic levels for the first time at the end of 2022, up from a low of 66% in Q2 of 2020 Telehealth visits fell to 5% of total visits in 2022, down from peak of 25% early in the pandemic Biosimilars now account for 25% of total volume of reference molecules prescribed in the U.S. The average... Read More

Revenue of $3,652 million GAAP Net Income of $289 million, Adjusted EBITDA of $851 million GAAP Diluted Earnings per Share of $1.53, Adjusted Diluted Earnings per Share of $2.45 R&D Solutions quarterly bookings of $2.6 billion, representing book-to-bill ratio of 1.28x R&D Solutions contracted backlog of $27.9 billion grew 10.1 percent year-over-year and 11.3 percent excluding the impact of foreign exchange Reaffirms... Read More

RESEARCH TRIANGLE PARK, N.C. / Apr 20, 2023 / Business Wire / IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announces the company has been recognized as a Leader in Customer Experience Platforms (CXP) by Everest Group for its Orchestrated Customer Engagement ( OCE ) platform. The IQVIA OCE... Read More

RESEARCH TRIANGLE PARK, N.C. / Apr 06, 2023 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2023 financial results before the market opens on Thursday, April 27, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor... Read More

RESEARCH TRIANGLE PARK, N.C. / Mar 14, 2023 / Business Wire / In 2022, global clinical trial activity remained resilient even as the COVID-19 pandemic stretched through the year, with a 1% decline in non-COVID trial activity compared to 2021. COVID-19 trials as a percentage of total trial activity dropped from 10% to 6% of the 5,756 total trials run in 2022. Non-COVID trial activity increased by 8% between 2019 and 2022,... Read More

RESEARCH TRIANGLE PARK, N.C. / Mar 01, 2023 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023 at 9:30 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at... Read More

RESEARCH TRIANGLE PARK, N.C. / Feb 23, 2023 / Business Wire / IQVIA (NYSE:IQV) has published its 2022 Environmental, Social and Governance (ESG) Report. The annual report provides a detailed account of the organization’s focus on reducing its environmental impact and commitment to accelerating positive outcomes for public health and patients. “At IQVIA our mission is to drive healthcare forward, improving patient outcomes... Read More

RESEARCH TRIANGLE PARK, N.C. / Feb 10, 2023 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended December 31, 2022. Fourth-Quarter 2022 Operating Results Revenue for the fourth quarter of $3,739 million increased 2.8 percent on a... Read More

RESEARCH TRIANGLE PARK, N.C. / Feb 09, 2023 / Business Wire / IQVIA ™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to FORTUNE magazine’s “World’s Most Admired Companies” list for the sixth consecutive year. Once again, IQVIA earned the first-place ranking within FORTUNE’s Health Care: Pharmacy and Other Services... Read More

Leading technology providers come together to bring innovative solutions addressing the unique business and compliance needs of the Greater China Region RESEARCH TRIANGLE PARK, N.C. / Jan 31, 2023 / Business Wire / IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announces the first life... Read More

RESEARCH TRIANGLE PARK, N.C. / Jan 25, 2023 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) will announce its fourth-quarter and full-year 2022 financial results before the market opens on Friday, February 10, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the... Read More

The COVID-19 pandemic continues to impact pharmaceutical markets globally, and is estimated to expand the net cumulative pharmaceutical market by $500 billion from 2020 through 2027 Highest volume growth is expected in Latin America, Asia and Africa, driven by a mix of population growth and expanded access. North America and Europe will see very low growth Demand for innovative drugs will drive oncology spending to... Read More

The healthcare marketing and analytics leader expands their Measurement Suite to include unprecedented audience and campaign insights. AUSTIN, Texas , Jan. 3, 2023 /PRNewswire/ -- Lasso , an IQVIA (IQV) business and provider of a leading healthcare marketing and analytics operating system, announced the integration of IQVIA's AIM XR (Audience Identity Manager® XR) into their operating system, giving over 4,000 medical... Read More